KCT0001545招募中未知
A randomized, open-label, single dose, 3-treatment, 3-period, 6-sequence crossover study to investigate the effect of food on the pharmacokinetics/pharmacodynamics and safety of CKD-519 after oral administration in healthy adult volunteers
Chong Kun Dang0 个研究点目标入组 42 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 42
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 55(Year)（—）
- 性别
- All
入选标准
- •1. Between 19 aged and 55 aged in healthy adult
- •2. Body weight more than 55kg in male, 50kg in female
- •3. Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)
- •4. If female, must include more than one among the items
- •- The menopause(there is no natural menses for at least 2 years)
- •- Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or other methods of infertility condition)
- •5. If men has sexual life with women of childbearing age, Necessarily he agrees that use condoms and do not sperm donation until two months during clinical trials and after the final dosage of investigational products
- •6. Those who fully understand about this clinical trials after enough hearing, and then decided to join the clinical trials by themselves and to comply with the precautions written consent
排除标准
- •1. Have clinically significant disease that hepatobiliary system(severe hepatic impairment, etc.), kidney(severe renal impairment, etc.), nervous system, immune system, respiratory system, endocrine system, haemato-oncology disease, cardiovascular system(heart failure, etc.) or mental illness, or a history of mental disease.
- •2. Have a gastrointestinal disease history that can effect drug absorption(Crohn's disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)
- •3. Hypersensitivity reaction or clinically significant hypersensitivity reaction in the history of drugs or additives.
- •4. An impossible one who participates in clinical trial including screening tests (medical history taking, BP, 12-lead ECG, physical examination, blood&urine laboratory test result) before 28 days the taking investigational products.
- •5. Defined by the following laboratory parameters
- •- AST, ALT>1.25* upper limit of normal range
- •- Total bilirubin>1.5* upper limit of normal range
- •- CPK>1.5* upper limit of normal range
- •- eGFR(using by MDRD method)<60mL/min/1.73m2
- •6. Sitting SBP>150mmHg or <90mmHg, sitting DBP>100mmHg or 50mmHg , after 5 minutes break.
- •7. Drug abuse or have a history of drug abuse shows a positive for urine drug test.
- •8. Pregnant or lactating women.
- •9. A heavy caffeine consumer(caffeine>5 cups/day), alcohol consumer(alcohol>210g/week), or smoker(cigarette>10 cigarettes/day)
- •10. Subject takes ethical drug or herbal medicine within 14 days, OTC(Over the counter drug) within 7 days before the beginning of study treatment but investigator determine that the taking drug affect this study or could affect the safety of subjects
- •11. Subject who takes inhibitor and inducers of drug metabolizing enzyme(Barbiturates etc.) within 30days.
- •12. Taking foods containing grapefruit within 7 days before the beginning of study treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7days before the beginning of study treatment)
- •13. Subject who treated with any investigational drugs within 90 days before the beginning of study treatment.
- •14. Previously donate whole blood within 60 days or component blood within 30days.
- •15. An impossible one who participants in clinical trial by investigator's decision including laboratory test result or another reason.
- •16. Positive for Serology test(Hepatitis B, Hepatitis C, HIV)
研究者
相似试验
已完成
不适用
The Pharmacokinetic Characteristics and Food Effect of Levodropropizine Controlled-Release Tablets Compared with Levodropropizine Immediate-Release TabletsDiseases of th respiratory systemKCT0002383Korea United Pharm48
已完成
不适用
A single-dose, 3-treatment, 3-period, 6-sequence crossover study in healthy male subjects to evaluate the pharmacokinetics of GLA5PR GLARS-NF1 tablet 150mg and LYRICA® capsule 75mgEndocrine, nutritional and metabolic diseaseKCT0001311GL PharmTech30
已完成
不适用
A study to compare the pharmacokinetics and safety/tolerability of BS-105 enteric-coated tablet A” or BS-105 enteric-coated tablet B” of Bio-Synectics to original drug in healthy male subjects (Pilot study)Certain infectious and parasitic diseasesKCT0004007Bio-Synectics9
已完成
不适用
Relative bioavailability study of two candidate tablet formulations of 16mg candesartan cilexetil (GW615775) compared with the reference product Atacand (16mg candesartan cilexetil, AstraZeneca) in healthy human subjects under fasting conditionsCTRI/2014/12/005269GlaxoSmithKline Research and Development Limited18
招募中
不适用
Relative bioavailability of montelukast sodium 5mg from two candidate chewable tablet formulations of GW483100 relative to one 5mg chewable tablet of reference montelukast sodium in healthy adult subjects under fasting conditionsCTRI/2015/03/005625GlaxoSmithKline Research and Development Limited18